Pre-mixed BPC-157 vials prescribed by licensed providers
- Starting at $4.52/day
- Pre-mixed sterile vials, no mixing at home
- Consult included, 100% online
Save $100 with a 1-month plan
We earn commissions from brands listed on this site, which influences how listings are presented.Advertising Disclosure
Our top recommendations, ranked on pharmacy sourcing, provider oversight, vial format and value.
Last updated November 2026
Pre-mixed BPC-157 vials prescribed by licensed providers
Save $100 with a 1-month plan
A cycled protocol: 8 weeks on, at least 4 weeks off
The lowest monthly rate on this list, in all 50 states
Injection or oral capsules at one all-in price
BPC-157 injections with optional subscription pricing
BPC-157 shipped fully reconstituted, ready to use
BPC-157 injections on 2-month plans
HIPAA Compliant · 100% Online · Licensed U.S. Providers
Seen cheaper research vials? See how they compare with Rugiet
BPC stands for "body protection compound." BPC-157 is a synthetic peptide built from 15 amino acids. Its sequence is taken from a protein found in human gastric juice, so most of the early research grew out of studies on how the stomach lining defends itself.
That origin makes it different from a peptide like sermorelin, which acts on one well-mapped receptor (GHRH) to raise growth hormone. BPC-157 has no single known receptor. Preclinical work instead points to several pathways at once:
It also leaves the body quickly. In animal metabolism studies its half-life is under 30 minutes. The liver processes it and the kidneys clear it.
A 2025 systematic review in HSS Journal screened 544 articles published between 1993 and 2024 and kept 36 studies. Of those, 35 were preclinical. Only 1 was clinical.
The animal results are consistent. Across muscle, tendon, ligament and bone injury models, BPC-157 improved functional, structural and biomechanical outcomes. In one 2003 study, rats with transected Achilles tendons healed faster when given BPC-157.
The human record is much smaller. A 2026 systematic review searched for human evidence through June 2026 and found 3 studies with 30 participants in total:
Reviewers rated all three as poor quality and the overall certainty of evidence as very low.
The knee study is often quoted, so its design matters. It was a retrospective chart review with phone follow-up and no control group. Of the 12 people who received BPC-157 alone, 11 reported meaningful relief.
BPC-157 is frequently paired with TB-500, a fragment of thymosin beta-4. Four patients in that knee study received the combination. No controlled human data exists on the pairing.
Put simply, the animal data is promising and points in one direction. The human data is too thin to say how well BPC-157 works, at what dose, or for whom. A provider who promises specific results is going past the evidence.
Stomach enzymes break down most peptides before they can be absorbed. That is the reason oral sermorelin underperforms the injected form. BPC-157 is the exception. It comes from gastric juice, lab research describes it as stable there, and animal studies have used oral dosing.
So oral is not automatically the weaker choice here. Providers tend to prescribe oral BPC-157 for gut-focused goals and subcutaneous injection for musculoskeletal recovery.
No human study has compared the two routes. None of the three published human studies used oral dosing at all.
Regulation adds a condition. HHS's October 2026 draft policy covers oral BPC-157 only where there is documentation of adequate oral bioavailability in humans.
Some sellers also offer nasal sprays. Intranasal use is not one of the routes the HHS draft policy lists for BPC-157.
Some programs ship BPC-157 as freeze-dried powder with reconstitution instructions. Others, including Rugiet and PeRx, ship it already in liquid form.
Mixing powder at home takes three steps: drawing bacteriostatic water, reconstituting the powder, and converting milligrams into syringe units for each dose. Each step is a chance for a dosing or sterility error. Pre-mixed liquid vials remove all three.
There is a trade-off. Once any peptide is in liquid form, it has a limited shelf window and needs refrigeration. Ask your provider how long a vial lasts after it is opened.
Rugiet ships pre-mixed sterile vials only.
BPC-157 is not approved by FDA for any use. Its regulatory status has moved several times in recent years:
The ten conditions include:
For a reader, the point is that enforcement discretion is not approval. The draft policy is narrow. Blends of BPC-157 with TB-500, nasal sprays and other salt forms fall outside it. The regulated route is a single-ingredient prescription from a licensed provider, filled by a licensed U.S. pharmacy.
Reported side effects include injection-site irritation, nausea, headache, flushing and digestive discomfort.
No large human safety studies exist. The small human studies reported no treatment-related adverse events, but with 30 people in total they cannot rule out uncommon effects.
Three groups should skip it or raise it with a provider first:
| Feature | Rugiet | Purityx Labs | Nexen Compounds | Medicina Labs |
|---|---|---|---|---|
| Product | Prescription BPC-157 | BPC-157 | "Wolverine" blend (BPC-157 + TB-500) | "Wolverine" blend (BPC-157 + TB-500) |
| What the seller says about human use | Prescribed by a licensed provider | Sold "for research" | "Not for human or veterinary use" | "Not for human consumption" |
| Licensed provider reviews your health history | Yes | No | No | No |
| Dispensed by a pharmacy on a prescription | Yes | No | No | No |
| Single active ingredient | Yes | Yes | No | No |
| Pre-mixed sterile vial, no mixing at home | Yes | No | No | No |
Many of the sellers that appear in a search for BPC-157 are research-chemical vendors, not prescribers.
Research vials usually cost less per vial. The lower price leaves several things out. A "research use only" or "not for human consumption" label means:
The 2025 HSS review identifies unregulated manufacturing and contamination as the main sources of possible harm.
On the prescription route, a licensed provider reviews your health history and a licensed U.S. compounding pharmacy fills a prescription written for you. HHS's draft policy applies only to licensed pharmacies and physicians compounding against a patient-specific prescription. It does not cover research-use-only sellers.
When comparing peptide programs, check:
Rugiet prescribes BPC-157 after an online consultation, as pre-mixed injectable vials compounded at licensed U.S. pharmacies.
Medical disclaimer: This content is for informational purposes only and is not medical advice. It does not replace a consultation with a licensed healthcare provider. Talk to a provider before starting BPC-157 or any other treatment.
Rugiet BPC-157 is a compounded drug product and requires a prescription. Compounded drugs are not approved by FDA and do not undergo review or verification by FDA for safety, effectiveness, or quality. Prescriptions require an online consultation with a licensed provider who will determine if a prescription is medically appropriate. Individual results may vary. Offered as part of a recurring subscription. Additional terms apply. Visit rugiet.com for details and important safety information. Pricing and product details for third-party brands were verified in November 2026 and may change. Ratings reflect our editorial assessment.